Association of Self-Reported Depression on the Lupus Impact Tracker with Glucocorticoid Therapy and Fibromyalgia in Systemic Lupus Erythematosus: Insights from the RELESSER-PROS Registry - Summary - MDSpire

Association of Self-Reported Depression on the Lupus Impact Tracker with Glucocorticoid Therapy and Fibromyalgia in Systemic Lupus Erythematosus: Insights from the RELESSER-PROS Registry

  • By

  • Inigo Rua-Figueroa

  • Julia Martínez-Barrio

  • Zulema Plaza

  • Norman Jiménez

  • Maria Galindo-Izquierdo

  • Esther Uriarte

  • Antonio Fernandez-Nebro

  • Jaime Calvo Alen

  • José Rosas

  • Javier Narváez

  • Elena Aurrecoechea

  • Mercedes Freire

  • Eva Tomero

  • Clara Sanguesa

  • Carlota Iniguez

  • Ana Perez

  • Sandra Garrote

  • Nuria Lozano-Rivas

  • Oihane Ibarguengoitia

  • Eva Salgado

  • Celia Erausquin

  • Tarek Carlos Salman Monte

  • Raúl Menor

  • Irene Altabás-González

  • Jorge Fragio Gil

  • Joan M. Nolla

  • Jose M. Pego-Reigosa

  • January 24, 2026

  • 0 min

Share

Objective:

To assess the prevalence of self-reported depression using LITQ7 and identify its longitudinal associations, including factors such as glucocorticoid therapy and fibromyalgia, in a cohort of SLE patients.

Key Findings:
  • 89.9% of patients reported depression at least once, with 34.6% reporting being depressed most of the time (p-value < 0.05).
  • 26.5% of patients reported persistent depressive symptoms across all five visits.
  • Significant associations were found between self-reported depression and greater organ damage (p-value < 0.05).
Interpretation:

The high prevalence of self-reported depression in SLE patients underscores the urgent need for effective monitoring and management of mental health in this population, particularly in relation to treatment strategies.

Limitations:
  • Reliance on self-reported measures may introduce bias, as patients may underreport or overreport symptoms based on various factors.
  • The study's observational nature limits causal inferences, making it difficult to establish direct relationships between variables.
Conclusion:

The findings underscore the importance of addressing depression in SLE patients, particularly in relation to glucocorticoid therapy and fibromyalgia.

Original Source(s)

Association of Self-Reported Depression on the Lupus Impact Tracker with Glucocorticoid Therapy and Fibromyalgia in Systemic Lupus Erythematosus: Insights from the RELESSER-PROS Registry

  • by Inigo Rua-Figueroa, Julia Martínez-Barrio, Zulema Plaza, Norman Jiménez, Maria Galindo-Izquierdo, Esther Uriarte, Antonio Fernandez-Nebro, Jaime Calvo Alen, José Rosas, Javier Narváez, Elena Aurrecoechea, Mercedes Freire, Eva Tomero, Clara Sanguesa, Carlota Iniguez, Ana Perez, Sandra Garrote, Nuria Lozano-Rivas, Oihane Ibarguengoitia, Eva Salgado, Celia Erausquin, Tarek Carlos Salman Monte, Raúl Menor, Irene Altabás-González, Jorge Fragio Gil , Joan M. Nolla, Jose M. Pego-Reigosa

  • January 24, 2026

Related Content

Clinical applications and challenges of CD40/CD40L signaling regulation in autoimmune diseases

Can RAIL Predict Lupus Nephritis Course?

Urine biomarker index was associated with kidney inflammation and future treatment response across visits.

Efficacy of Splenectomy in Treating Refractory Autoimmune Hemolytic Anemia Linked to Systemic Lupus Erythematosus: A Case Study with Mechanistic Analysis